The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer

NCT06497777 | Recruiting

• 1 other identifier: 202405082RINB
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.

Conditions

Pancreas Adenocarcinoma; MicroRNA

Keywords

MicroRNA; Pancreas Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• Ratio of the target microRNA in patients with and without pancreatic adenocarcinoma.

  24 hours

Study Arms (2)

Pancreatic adenocarcinoma

Pancreatic adenocarcinoma which are proven by pathology, before initiation of anti-cancer treatment.

Genetic: MicroRNA (mir-642b-3p)

Healthy control

People who do not have pancreatic disease.

Interventions

MicroRNA (mir-642b-3p) GENETIC

A circulating microRNA in the blood of pancreatic cancer patients.

Pancreatic adenocarcinoma

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with pancreatic ductal adenocarcinoma which are proven by pathology.

You may qualify if:

• Pancreatic ductal adenocarcinoma
• Proven by pathology
• Patients who have not received anti-cancer therapies

You may not qualify if:

• Less than 20 years old
• Unable to provide inform and consent
• Patients who have active malignancy other than pancreatic adenocarcinoma
• Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing
• Life expectancy less than 3 months

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Hospital

Taipei, 100225, Taiwan

RECRUITING

MeSH Terms

Interventions

MicroRNAs

Intervention Hierarchy (Ancestors)

RNA, Antisense; Antisense Elements (Genetics); Nucleic Acids, Nucleotides, and Nucleosides; RNA; Nucleic Acids; RNA, Small Untranslated; RNA, Untranslated

Central Study Contacts

Weng Fai Wong, Master of Science

CONTACT

886-972652272; 106290@ntuh.gov.tw

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 5, 2024
• First Posted: July 12, 2024
• Study Start: July 6, 2024
• Primary Completion: June 1, 2025
• Study Completion (Estimated): June 1, 2026
• Last Updated: July 12, 2024

Record last verified: 2024-06

Locations

TW (1)